Skip to main content

Table 1 List of approved ATP-competitive inhibitors and respective indications

From: Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

First generation

Imatinib

First-line and second/subsequent-linea, all disease phases

Second generation

Dasatinib

First-line and second/subsequent-line, all disease phases

Nilotinib

First-line and second/subsequent-line, CP and AP only

Bosutinib

Third-line or when imatinib, dasatinib or nilotinib are not considered appropriate, all disease phases

Third generation

Ponatinib

Second/subsequent-line if T315I+ or when no other TKI is considered appropriate, all disease phases

  1. abeing the weaker of all, imatinib is rarely considered as second/subsequent line option especially in case of resistance
Back to article page

Molecular Cancer

ISSN: 1476-4598